首页 / 院系成果 / 成果详情页

dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study 会议论文

编号：

CC28811A885787D32E0D08CA7B09CAE3
作者：

Jian, Yuan^[1];Chang, Long^[2];Shi, Minxia^[3];Sun, Ying^[4];Chu, XiaoXia(初晓霞)^[5]Xue, Hua^[6];Huang, Wenrong^[7];Shen, Xuliang^[8];Ma, Jie^[9];Jia, GuoBong^[10];Feng, YaQing^[11];Xi, ZhenFang^[12];Zhao, YanHong^[13];Ma, Yanping^[14];Xiao, Jing^[15];Ma, GuangYu^[16];Wang, QingMing^[17];Bao, Li^[18];Dong, Yujun^[19];Zhou, HeBing^[20];Sun, Chunyan^[21];Su, GuoHong^[22];Yan, Yan^[23];Qimuge, SaiYin^[24];Su, Liping^[25];Sun, Jingnan^[26];Tian, Weiwei^[27];Li Sun, Xiu^[28];Jing, Hongmei^[29];Gao, Da^[30];Zhu, HongHu^[1,31];Chen, Wenming^[1];Li, Jian^[2];Gao, Wen^[1];
语种：

英文
会议名称：

BLOOD
收录：
高质量科技期刊分级目录：

T1
推荐引用方式
GB/T 7714：

Jian Yuan,Chang Long,Shi Minxia, et al. Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study [J].BLOOD,2025,146:5818-5819.
APA：

Jian Yuan,Chang Long,Shi Minxia,Sun Ying,&Gao Wen.(2025).Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study .BLOOD,146:5818-5819.
MLA：

Jian Yuan, et al. "Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study" .BLOOD 146(2025):5818-5819.
入库时间：

2/2/2026 9:06:46 AM
更新时间：

2/11/2026 9:33:04 PM

浏览次数：8  下载次数：0

分享到：

浏览次数：8

下载次数：0

打印次数：0